Robert Georgantas's Insider Trades & SAST Disclosures
Robert Georgantas's most recent trade in Biodesix Inc was a trade of 12,000 Common Stock done at an average price of $1.2 . Disclosure was reported to the exchange on Nov. 21, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Georgantas.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.15 per share. | 21 Nov 2022 | 12,000 | 38,114 | - | 1.2 | 13,800 | Common Stock |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2022 | 5,646 | 27,890 | - | - | Common Stock | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2022 | 3,676 | 11,026 | - | - | Restricted Stock Units | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2022 | 1,970 | 25,624 | - | - | Restricted Stock Units | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.04 per share. | 08 Nov 2022 | 991 | 26,899 | - | 1.0 | 1,032 | Common Stock |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.02 per share. | 08 Nov 2022 | 785 | 26,114 | - | 1.0 | 799 | Common Stock |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2022 | 5,647 | 23,930 | - | - | Common Stock | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2022 | 3,675 | 14,702 | - | - | Restricted Stock Units | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2022 | 1,972 | 27,594 | - | - | Restricted Stock Units | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.53 per share. | 08 Aug 2022 | 1,686 | 22,244 | - | 2.5 | 4,263 | Common Stock |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2022 | 5,647 | 20,287 | - | - | Common Stock | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2022 | 3,676 | 18,377 | - | - | Restricted Stock Units | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.83 per share. | 09 May 2022 | 2,004 | 18,283 | - | 1.8 | 3,667 | Common Stock |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2022 | 1,971 | 29,566 | - | - | Restricted Stock Units | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 22,722 | 22,722 | - | - | Stock Options (Right to buy) | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2022 | 31,537 | 31,537 | - | - | Restricted Stock Units | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2022 | 22,053 | 22,053 | - | - | Restricted Stock Units | |
| Biodesix Inc | Robert Georgantas | Director, SVP, Rsrch & Transl Science | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2021 | 10,219 | 19,262 | - | - | Stock Option (Right to buy) | |
| Biodesix Inc | Robert Georgantas | Director, SVP, Rsrch & Transl Science | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.77 per share. | 05 Apr 2021 | 10,219 | 10,774 | - | 0.8 | 7,869 | Common Stock |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 2,843 | 2,843 | - | - | Stock Options (Right to buy) | |
| Biodesix Inc | Robert Georgantas | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 2,842 | 5,685 | - | - | Stock Options (Right to buy) | |
| Biodesix Inc | Robert Georgantas | Director, SVP, Rsrch & Transl Science | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 30 Oct 2020 | 555 | 555 | - | 18 | 9,990 | Common Stock |
| Biodesix Inc | Robert Georgantas | Director, SVP, Rsrch & Transl Science | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 30 Oct 2020 | 100 | 100 | - | 18 | 1,800 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges